Article

NVG-111 Generates Early Efficacy With Manageable Safety in Relapsed/Refractory CLL, MCL

Author(s):

The ROR1-targeting bispecific T-cell engager NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

cll, mcl

The ROR1-targeting bispecific T-cell engager (BiTE) NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL), according to findings from the phase 1 NVG111-101 trial (NCT04763083).

Data presented at the 2022 ASCO Annual Meeting showed that in 5 patients with CLL, NVG-111 generated responses in 4 patients, including a complete response (CR) in 2 patients and a partial response in 2 patients.

In the 2 patients to achieve a CR, both had undetectable minimal residual disease (MRD) at last assessment. In long-term follow-up of 1 complete responder, the patient still had undetectable MRD at 6 months following the completion of NVG-111. The other complete responder will enter long-term follow-up after the completion of a final cycle of NVG-111.

The 2 partial responders are in long-term follow-up. The fifth patient experienced only a cytokine response, and the patient was off study treatment following disease progression.

The 1 patient with MCL treated with NVG-111 achieved a PR, and that patient is currently in long-term follow-up.

NVG-111 is a novel humanized, tandem single-chain variable fragment ROR1 x CD3 BiTE that elicits potent tumor killing by engaging a membrane-proximal epitope in the membrane proximal frizzled domain of ROR1 and redirecting T-cell activity.

The NVG111-101 trial is a first-in-human study evaluating the safety and efficacy of NVG-111 in hematological malignancies before it is investigated in solid tumors.

Phase 1 of the study is enrolling up to 36 patients with relapsed/refractory CLL, small lymphocytic lymphoma, or MCL who received at least 2 prior lines of systemic therapy and had stable disease or a PR following their last line of therapy.

The first 3 cohorts featured 1 patient each, and these patients were subjected to accelerated dose titration, with treatment administered daily for 21 days on, 7 days off, in every 28-day cycle. Patients received treatment for 3 cycles, or up to 6 cycles where applicable for each cohort. The patient in cohort 1 received 0.3 μg of intravenous (IV) NVG-111 per day for each cycle. In cohort 2, the patient received 1 μg of IV NVG-111 per day in cycle 1, 3 μg in cycle 2, and 10 μg in cycle 3. The patient in cohort 3 was given 3 μg of IV NVG-111 per day in cycle 1, 10 μg in cycle 2, and 30 μg in cycle 3.

In cohort 4, 3 patients received 30 μg of IV NVG-111 per day in all 3 cycles. Notably, all patients remained on salvage ibrutinib (Imbruvica) during study treatment.

The primary end point of the trial was safety, including adverse effects (AEs), serious AEs, and dose-limiting toxicities. Secondary end points included anti-tumor activity, pharmacokinetics, and biomarkers.

Regarding safety, all 3 patients in cohort 4 experienced grade 1 cytokine release syndrome (CRS), and it resolved in all patients. No patients in the first 3 cohorts experienced CRS. One patient in cohort 4, who had CLL, experienced grade 3 immune effector cell-associated neurotoxicity syndrome during the first cycle of treatment. As a result, NVG-111 was stopped after 48 hours, and the patient was given dexamethasone and tocilizumab (Actemra).

No grade 3 or higher AEs or serious AEs were reported. No grade 2 AEs were reported in any patients in cohorts 1, 2, and 3. In cohort 4, all patients experienced multiple grade 1/2 AEs.

An analysis of pharmacokinetics showed that circulating NVG-111 levels from patients treated with less than 10 μg per day were below the 250 pg/mL threshold for detection. At 10 μg/day, the average steady state (Avgcss) serum concentration was 168 pg/mL to 228 pg/mL. At 30 μg/day, the Avgcss serum concentration was 425 pg/mL to 610 pg/mL.

The biomarker analysis showed that a transient increase in cytokines detected with varying kinetics at all dose levels.

The phase 1 trial is ongoing, with additional cohort expansion planned for patients with CLL and MCL. The recommended phase 2 dose has yet to be determined. Additionally, step-up dosing and NVG-111 monotherapy are being evaluated in challenging patients who are at the end of line.

Reference

Jasani P, Townsend W, Asher S, et al. First-in-human phase 1 study of a ROR1 targeting bispecific T cell engager (NVG-111) shows evidence of efficacy in patients with relapsed/refractory CLL and MCL. J Clin Oncol. 2022;40(suppl 16):7535. doi:10.1200/JCO.2022.40.16_suppl.7535

Related Videos
Jean L. Koff, MD, MS, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute
Kathleen A. Dorritie, MD
Leo I. Gordon, MD
Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD
John Seymour, MBBS, FRACP, PhD
A panel of 5 experts on CLL
Jean L. Koff, MD, MS
A panel of 5 experts on CLL
A panel of 5 experts on CLL